So my favorite presentation at CTAD was delivered by Gemma Salvadó of Barcelona Beta and Lund University, and she showed how you can combine together plasma percent p-tau217 and MTBR-tau243 to stage individuals biologically within the Alzheimer’s disease continuum. And these plasma biomarker-based stages agreed amazingly well with amyloid PET and tau PET-based stages. And that’s really remarkable because, of course, doing an amyloid PET scan and a tau PET scan is very expensive...
So my favorite presentation at CTAD was delivered by Gemma Salvadó of Barcelona Beta and Lund University, and she showed how you can combine together plasma percent p-tau217 and MTBR-tau243 to stage individuals biologically within the Alzheimer’s disease continuum. And these plasma biomarker-based stages agreed amazingly well with amyloid PET and tau PET-based stages. And that’s really remarkable because, of course, doing an amyloid PET scan and a tau PET scan is very expensive. In the U.S., it’s typically over $10,000, certainly, to do both of those scans. And those PET scans are helpful because they tell you about where someone is in the course of disease biologically and also whether they’re likely to respond to certain treatments. And what Gemma’s work suggests is that you could get similar kinds of information from a blood test, which, of course, would be much cheaper and easier. So I find that very exciting that we will be able to do this with blood. Of course, multiple ptau assays are available, and we expect that MTBR-tau243 will become increasingly available, and other companies are also working on MTBR-tau243, as well as other biomarkers of tau pathology. So overall, this looks very promising that we’ll be able to stage Alzheimer’s disease biologically with blood tests.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
